Systemic inflammation in malignant pleural mesothelioma: Is neutrophil-to-lymphocyte ratio a prognostic index?

Felice Mucilli, Pierpaolo Campese, Luigi Guetti, Barbara Maggi, Marco Prioletta, Mirko Barone, Antonia Rizzuto and Rosario Sacco

1Department of General and Thoracic Surgery, University “G. d’Annunzio” -Chieti, Italy
2Department of Medical and Surgical Sciences, University “Magna Graecia”- Catanzaro, Italy

Abstract
Malignant Pleural Mesothelioma (MPM) is an aggressive, asbestos-related tumor that arises from the mesothelium. It is a neoplasm with an increasing incidence with a poor and a dismal prognosis. Inflammation plays a crucial role in the initiation and tumor progression. In addition, the history of MPM is characterized by symptoms referred to increased inflammatory responses such as fever, sweating and loss of weight. Recent studies have identified the neutrophil-to-lymphocyte ratio (NLR) as a feasible and simple marker of systemic inflammation. The Authors report a retrospective study in 54 patients with malignant pleural mesothelioma (MPM). MPM patients were more likely to be male (75.9% versus 24.1%) with a median age of 67 years. The epithelial histotype was predominant (77.8%) compared to the biphasic (11.1%), sarcomatous (9.5%) and desmoplastic (1.9%) ones. Neutrophil-to-Lymphocyte ratio (NLR) was assessed at diagnosis with a mean value of 4.31. The aim of the study was to test bivariate correlates between independent factors (age, sex, histology, NLR, lymphocyte count, lymph node involvement) and the overall survival of the population under investigation. The median overall survival (OS) in the general population included in the study was 13 months. Median Disease Free Interval (DFI) was 3 months. Patients with the epithelial histotype survived significantly longer than those presenting with sarcomatoid, biphasic or desmoplastic subtypes (15 months versus 2, 8 and 10 months respectively; p<0.001). Patients with NLR<3 showed a median overall survival of 22 months, while 3<NLR<5 and NLR>5 ones had a poorer survival rate (12 and 8 months respectively). There was evidenced of a strong correlation between patients with inflammation index less than three and overall survival (p<0.001). The Neutrophil-to-Lymphocyte Ratio (NLR) can be an independent, easily reproducible and comparable prognostic index in patients with malignant pleural mesothelioma.

Abbreviations: MPM: Malignant Pleural Mesothelioma, NLR: Neutrophil to Lymphocyte Ratio, OS: Overall Survival, DFI: Disease Free Interval

Introduction
Malignant Pleural Mesothelioma (MPM) is an aggressive, asbestos-related tumor that arises from the mesothelium [1]. It is a neoplasm with an increasing incidence [2]. Although numerous therapeutic options in patients with malignant pleural mesothelioma have been taken, the disease presents a poor and dismal prognosis [3] with a survival rates average 9-12 months [4-8].

Numerous studies report evidences about factors associated with prolonged survival and their impact on the disease’s evolution. These factors include demographic characteristics (eg. sex, age), analytes (absolute value of leukocytes, lymphocytes) and tumor characteristics (histology). In this regard, the European Organisation for Research and Treatment of Cancer (EORTC) and the Cancer and Leukemia Group B have drafted two prognostic indexes for patients with MPM [9-12]. Inflammation plays a crucial role in the initiation and tumor progression [13]. In addition, the history of MPM is characterized by symptoms referred to an increased inflammatory response such as fever, sweating and loss of weight [14-17]. As mentioned, the indices of inflammation may play a prognostic role in patients with malignant pleural mesothelioma. Recent studies have identified the neutrophil-to-lymphocyte ratio (NLR) as a feasible and simple marker of systemic inflammation [18-22]. However, available data are conflicting [23,24].

Patients and methods
Study and analysis
We report a retrospective study in patients with malignant pleural mesothelioma (MPM) conducted over the last decade (2004-2015). We proceeded to a descriptive and observational demographic study. In the second part of the analysis, survival rates were tested in the general population and in selected cohorts (NLR value, histology, lymph node involvement, therapeutic strategy). Finally, a bivariate analysis was carried out to identify positive independent prognostic factors in the population.

The analysis of survival and related ratios was performed by Kaplan and Meier’s method, while in the bivariate analysis values of p<0.005 were considered significant.

Patient characteristics
Data on 54 patients with MPM, admitted consecutively to our Institution from 2004 to 2015, were collected. MPM patients were...
more likely to be male (75.9% versus 24.1%) with a median age of 67 years [min. 46 – max. 85 (95% CI 62.6 – 68.12)] (Table 1).

The epithelial histotype was predominant (77.8%) compared to the biphasic (11.1%), sarcomatous (9.5%) and desmoplastic (1.9%) ones (Figure 1).

Of 54 patients, 53.7% were current or ex smokers, whereas 46.3% had no history of smoking. In 31.5% cases, a direct asbestos exposure (e.g. work or home) was assessed, in 16.7% an indirect one and in 51.9% patients no risk factors were recognized.

In total, 35.2% of patients received neoadjuvant chemotherapy. On immunohistochemistry, calretinin expression was showed in 87% of patients (92.8% in epithelial, 66.6% in biphasic and 60% in sarcomatoid). All patients at diagnosis were staged according to the AJCC’s staging system [25], with 59.3% having an early stage (I-II stage) and 40.7% an advanced stage disease (III-IV stage).

Neutrophil-to-Lymphocite ratio (NLR) was assessed at diagnosis with a mean value of 4.31 [min. 0,9 - max. 16.5 (95% CI 3.46-5.16)]. Clustering this series, 44.4% of patients had a NLR<3, 25.9% a 3<NLR<5 and 29.6% a NLR>5.

Radical surgery, in the form of extrapleural pneumonectomy, was undergone by 46.3% of the study population and, in 9.3% of them, a hyperthermic intrathoracic chemotherapy (HITOC) was offered. In 7.4%, a Waller’s extended pleurectomy and decortication was conducted. Remanents were referred to palliative surgery such as pulmonary wedge resections, partial pleurectomy/decortication and pleural biopsies. 30-day mortality was 5.6%.

Results

The median overall survival (OS) in the general population included in the study was 13 months (95% CI 11.48-14.51) (Figure 2 and Table 2). Median Disease Free Interval (DFI) was 3 months. Clustering this data according to the AJCC’s Pleural Mesothelioma staging system, stage IA patients showed a median OS of 49 months, whereas stage IV ones was only of 5 months (Table 3).

Patients with the epithelial histotype survived significantly longer than those presenting with sarcomatoid, biphasic or desmoplastic

| Table 1. Patient characteristics with malignant pleural mesothelioma, 2004 -2015 (n=54). |
|----------------------------------------|
| Demographic characteristics            |
| Sex                                    |
| Male                                   | 41 | 75.9 |
| Female                                 | 13 | 24.1 |
| Median age                             | 67 |      |
| Smoking                                |
| Current/ex smokers                     | 29 | 53.7 |
| No                                     | 25 | 46.3 |
| Asbestos exposure                      |
| Direct                                 | 17 | 31.5 |
| Indirect                               | 9  | 16.7 |
| No                                     | 28 | 51.9 |
| Clinical and pathological characteristics |
| Calretinin expression                  |
| Epithelial                             | 47 | 87   |
| Biphasic                               | 6  | 11.1 |
| Sarcomatoid                            | 5  | 9.5  |
| NLR                                    |
| NLR < 3                                | 24 | 44.4 |
| 3 < NLR < 5                            | 14 | 25.9 |
| NLR > 5                                | 16 | 29.6 |
| Histotype                              |
| Epithelial                             | 42 | 77.8 |
| Biphasic                               | 6  | 11.1 |
| Sarcomatoid                            | 5  | 9.5  |
| Desmoplastic                           | 1  | 1.9  |
| Stage disease                          |
| Early stage ( I-A-II)                  | 32 | 59.3 |
| Advanced stage (III-IV)                | 22 | 40.7 |
| Treatment characteristics              |
| Neoadjuvant chemotherapy               | 19 | 35.2 |
| Radical Surgery                        |
| P/D                                    | 4  | 7.4  |
| EPP                                    | 25 | 46.3 |
| EPP-HITOC                              | 5  | 7.4  |
| Palliative surgery                     |
| Pulmonary wedge resection/ lobectomy   | 2  | 3.8  |
| Partial P/D                            | 5  | 9.3  |
| Pleural biopsies                       | 18 | 33.3 |

Figure 1. Malignant pleural mesothelioma histotypes.

Figure 2. General population overall survival.
subtypes (15 months versus 2, 8 and 10 months respectively; p<0.001) (Figure 3). The presence of an intrathoracic lymph node involvement (hilar or mediastinal) is a decisive staging parameter. In fact, N+ disease (N1, N2 or N3) correlated with a median survival of 12 months (95% CI 8.25 to 15.74), while N0 one with a median of 21 months (95% CI 14.83 to 28.94). Neutrophil-to-Lymphocyte Ratio (NLR) was defined as the absolute neutrophil count divided by the absolute lymphocyte count. Although recent reports [26-28] in the Literature indicate that a NLR more than 5 can be considered high, Authors decided to review this cut-off bringing it to a nominal value of 3 in order to understaging them and to evaluate any difference from NLR<3 patients and NLR<5 patients in terms of survival. According to this procedure, general population was clustered.

Patients with NLR<3 showed a median overall survival of 22 months (95% CI 16.54-27.45), while 3<NLR<5 and NLR>5 ones had a poorer survival rate (12 and 8 months respectively) (Figure 4). In a bivariate analysis between these groups according to survival rates, a strong correlation between patients with inflammation index less than three and overall survival was evidenced (p<0.001). It was noted the same result, although with lesser statistical significance, among patients with NLR<5 and survival (p<0.005). Therefore, it can be argued the absolute ratio between neutrophil and lymphocytes may be considered an independent prognostic index in patients with malignant pleural mesothelioma. By dividing the population according to the surgical therapeutic strategy (e.g. radical and palliative surgery), in the first group (extrapleural pneumonectomy, total pleurectomy/decortication) it was noted a median survival of 22.5 months (95% CI 15.55-29.53), as opposed to the group that underwent palliative surgery, due to the extension of the disease and/or poor performance status, where a median survival of 11 months (95% CI 11.48-14.51) was assessed.

Patients who underwent to extrapleural pneumonectomy (EPP) had a median overall survival of 13 months compared to that of pleurectomy/decortication alone (11 months). No statistical differences were noted between this two procedures (p=0.09), although EPP present higher perioperative morbidity rates than pleurectomy (21.8% vs. 9.3%). Finally, we evaluated the role of the intraoperative intrathoracic chemotherapy (HITOC) in patients amenable to radical surgery. Median survival rates in patients undergoing EPP and palliative surgery were 22.5 months (95% CI 15.55-29.53) and 11 months (95% CI 11.48-14.51) respectively.

Table 2. Malignant pleural mesothelioma: Overall survival and disease free survival.

| Disease Characteristics | Median (OS) | 95% Confidence Interval |
|-------------------------|-------------|-------------------------|
| Stage                   |             |                         |
| IA                      | 49.00       | 21.84-76.16             |
| IB                      | 28.00       | 8.43-47.57              |
| II                      | 13.00       | 11.89-14.11             |
| III                     | 7.00        | 4.48-9.52               |
| IV                      | 5.00        | 0.00-13.58              |
| Histotype               |             |                         |
| Epithelial              | 15.00       | 12.05-17.95             |
| Sarcomatoid             | 2.00        | 1.12-2.81               |
| Biphasic                | 8.00        | 0.00-16.47              |
| Desmoplastic            | 10.00       |                         |
| Lymph Node              |             |                         |
| N+                      | 12.00       | 8.25-15.74              |
| N0                      | 21.00       | 14.83-28.94             |
| Clinical Characteristics |             |                         |
| Neutrophil-to-Lymphocyte Ratio (NLR) |    |                         |
| NLR < 3                 | 22.00       | 16.54-27.45             |
| NLR < 5                 | 16.00       | 12.42-19.44             |
| NLR > 5                 | 8.00        | 6.35-9.52               |
| Treatment strategy      |             |                         |
| Radical surgery         |             |                         |
| Extrapleural pneumonectomy, total pleurectomy/decortication | 22.50 | 15.55-29.53 |
| Palliative surgery      |             |                         |
| Partial pleurectomy/ decortication, pulmonary wedge resections/lobectomy, Pleural biopsy | 11.00 | 11.48-14.51 |
| EPP vs. P/D             |             |                         |
| EPP                     | 13.00       | 9.77-16.22              |
| P/D                     | 11.00       | 8.00-13.27              |
| EPP vs. EPP+HITOC       |             |                         |
| EPP                     | 13.00       | 9.77-16.22              |
| EPP+HITOC               | 19.60       | 11.51-27.69             |

Table 3. Malignant Pleural Mesothelioma: bivariate analysis and correlations.

| Disease Characteristics | Median (OS) | 95% Confidence Interval |
|-------------------------|-------------|-------------------------|
| Stage                   |             |                         |
| IA                      | 49.00       | 21.84-76.16             |
| IB                      | 28.00       | 8.43-47.57              |
| II                      | 13.00       | 11.89-14.11             |
| III                     | 7.00        | 4.48-9.52               |
| IV                      | 5.00        | 0.00-13.58              |
| Histotype               |             |                         |
| Epithelial              | 15.00       | 12.05-17.95             |
| Sarcomatoid             | 2.00        | 1.12-2.81               |
| Biphasic                | 8.00        | 0.00-16.47              |
| Desmoplastic            | 10.00       |                         |
| Lymph Node              |             |                         |
| N+                      | 12.00       | 8.25-15.74              |
| N0                      | 21.00       | 14.83-28.94             |
| Clinical Characteristics |             |                         |
| Neutrophil-to-Lymphocyte Ratio (NLR) |    |                         |
| NLR < 3                 | 22.00       | 16.54-27.45             |
| NLR < 5                 | 16.00       | 12.42-19.44             |
| NLR > 5                 | 8.00        | 6.35-9.52               |
| Treatment strategy      |             |                         |
| Radical surgery         |             |                         |
| Extrapleural pneumonectomy, total pleurectomy/decortication | 22.50 | 15.55-29.53 |
| Palliative surgery      |             |                         |
| Partial pleurectomy/ decortication, pulmonary wedge resections/lobectomy, Pleural biopsy | 11.00 | 11.48-14.51 |
| EPP vs. P/D             |             |                         |
| EPP                     | 13.00       | 9.77-16.22              |
| P/D                     | 11.00       | 8.00-13.27              |
| EPP vs. EPP+HITOC       |             |                         |
| EPP                     | 13.00       | 9.77-16.22              |
| EPP+HITOC               | 19.60       | 11.51-27.69             |

Figure 3. Overall survival according to histological pattern.

Figure 4. Overall survival according to Neutrophil-to-Lymphocyte Ratio clusters.
Discussion

Cancer is the leading cause of disease worldwide with 14.1 million of new cancer cases diagnosed in 2012 and it remains the leading cause of death with 8.2 million cancer deaths recorded in the same year [29]. Malignant pleural mesothelioma (MPM) is an aggressive cancer arising from mesothelial surfaces such as pleura (65%-70%), peritoneum (30%), tunica vaginalis testis, and pericardium (1%-2%) [30].

MPM is a rare cancer, difficult to treat and commonly associated with environmental or occupational exposure to asbestos [31]. It is subtyped into three main forms according to the histological pattern (epithelial, sarcomatoid and biphasic), thought other patterns, such as desmoplastic, are known [16]. Prognosis is poor and dismal [32].

In Europe the incidence is 20 cases per million, but this value presents a high variability between different nations [33]. It recognizes a high latency and tumor initiation time; infact, as reported by the Italian Registry of Mesothelioma (ReNaM Study Group), the latency period between exposure to asbestos and the onset of the disease is about 44 years [34]. In Literature latency periods of less than 10 years are very rare. Some Authors report that a prolonged latency can be attributed to a less heavy exposure, recognizing a direct correlation between the amount of asbestos exposure and the onset of pleural mesothelioma [35]. Data still remain controversial [36].

MPM is considered an asbestos-related disease (ARD); in fact, pathophysiological processes are common to professional pneumoconiosis such as chronic inflammation resulting in pleural plaque formation due to asbestos fiber retention [37], promoting pro-inflammatory effects [38-40] and genotoxicity [41-43].

It is now widely recognized the outcome of cancer patients is not only determined by tumor, but also by interactions between the tumor and patient-related factors (age, sex, health status, comorbidities, microenvironment, genetic) [44]. In this regard, the role of inflammation and cytokine interaction between tumor and naive cells was investigated. These studies have demonstrated the critical role of inflammation [45,46]. In particular host response has been recognized as an independent prognostic factor in many tumors. Although the mechanisms seem still unclear, many inflammatory processes influencing important patient-related factors such as nutritional status, functional, performance status and immunological decline have been demonstrated [47,48]. Moreover, protracted inflammation alters the balance [49] and activation of proliferative cellular pathways [23,50] perpetuating oncogenic stimuli. The neutrophil-to-lymphocyte ratio (NLR) is recognized as an independent prognostic factor in many cancers [51-53], although in Literature, opinions are conflicting (heterogeneity of populations, heterogeneity of cancer, chemotherapy).

A prognostic role for NLR in patients with Malignant Pleural Mesothelioma has been reported in a number of series, which are summarized in Table 4.

In 2010, Kao SC et al. [18] in a retrospective series of 173 MPM patients, showed NLR was an independent predictor for poor overall survival in such patients and that this index could stratify patients with survival difference. In our study, we confirm this trend clustering the population according to NLR. As reported by Guthrie et al. [54], in a meta-analysis conducted on 37,000 patients and more than 60 studies, a prognostic value of NLR was noted in 42 of them (non-randomized cohorts, operable patients, patients receiving neoadjuvant, adjuvant and inoperable patients).

Five studies [18,55-58], comprising 1113 patients, reported the prognostic value of the NLR in patients with primary thoracic tumors. In these patients, NLR had a prognostic value for both disease-free interval for and overall survival. The analysis also showed how the index tendency during the medical therapy presented a prognostic value. In fact, the normalization of the NLR, as expressed in the studies by Cedres, was predictive of improved survival.

For malignant pleural mesothelioma, data in the literature are conflicting. Meniawy TM et al. [12] reported that in 321 patients with malignant pleural mesothelioma, CALGB and EORTC models but not NLR had prognostic value.

In our study, although it is a limited 54 patients non randomized cohort one, we noted an independent prognostic value of NLR. Our retrospective study included a mixed cohort of patients clustered by age, histology, exposure to asbestos and therapeutic strategy. Tumor staging was performed according to the AJCC’s staging system. The descriptive analysis of the clinical and therapeutic characteristics recorded has highlighted significant correlations between epithelial subtype, absence of nodal involvement (N0 disease) and overall survival.

We have adopted an absolute threshold of NLR lower than that reported in Literature (NLR<3) in order to highlight significant differences by understaging these patients. In our experience, there is a survival advantage in patients with suboptimal index values rather than those with high values. We believe that a low ratio is an expression of a lower host immune response and therefore it prevents the onset of clinical features of chronic inflammation (fever, dysproteinemia,

Table 4. Prognostic value of NLR in MPM patients.

| Study | Centre | Tumor | N       | p-value   | NLR threshold |
|-------|--------|-------|---------|-----------|---------------|
| Linton A. (2014) [59] | Sydney (AUS) | MPM | 919 | < 0.001 | 5 |
| Clive AO (2014) [60] | Bristol (UK) | MPM | 67/83 (UK Cohort 2) | < 0.001 | 5 |
| Abakay O (2014) [61] | Diyarbakir (TUR) | MPM | 155 | < 0.001 | 3 |
| Anevlavis S (2014) [62] | Alexandroupolis (GR) | MPM | 90 | 0.002 | continuous |
| Kao SC (2013) [19] | Sydney (AUS) | MPM | 148 | 0.01 | 3 |
| Pinato DL (2012) [21] | London (UK) | MPM | 171 | 0.0008 | continuous |
| Kao SC (2011) [22] | Sydney (AUS) | MPM | 85 | < 0.01 | 3 |
| Kao SC (2010) [18] | Sydney (AUS) | MPM | 173 | < 0.001 | 5 |

MPM: Malignant Pleural Mesothelioma
weight loss), factors definitely recognized as prognostically negative. At the same time, we do not think that NLR is a direct expression of the stage of the disease, as we have noted also in patients with advanced stage disease (stage III-IV), low values of the index were noted. In this case, we believe that in a metastatic patient, a low NLR could be an expression of the exhaustion of proinflammatory processes and of clinical manifestations related characteristics of the terminal disease.

Conclusions

In conclusion, we believe that the Neutrophil-to-Lymphocyte Ratio can be an independent, easily reproducible and comparable prognostic index in patients with malignant pleural mesothelioma. We hope future prospective studies about it in order to validate a universally shared decision.

Compliance with ethical standards

The authors have no conflict of interest to be disclosed. The article is in accordance with ethical standards. The article does not contain any studies with human participants performed by the authors. For this type of study, no formal consent is not required. It is an anonymous study referring only to clinical data.

References

1. Kao SC, Reid G, Lee K, Vardy J, Clarke S, et al. (2010) Malignant mesothelioma. *Intern Med J* 40: 742-750. [Crossref]
2. Froudarakis ME (2012) Pleural diseases in the molecular era - time for more answers: introduction. *Respiration* 83: 2-4. [Crossref]
3. Linton A, Vardy J, Clarke S, van Zandwijk N (2012) The tickling time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. *Crit Rev Oncol Hematol* 84: 200-212. [Crossref]
4. Tanrikulu AC, Abakay A, Kaplan MA, Küçüköner M, Palanci Y, et al. (2010) A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. *Respiration* 80: 480-487. [Crossref]
5. Vogelzang NJ (1992) Malignant mesothelioma: diagnostic and management strategies for 1992. *Semin Oncol* 19: 64-71. [Crossref]
6. Schouwink H, Korse CM, Bonfert JM, Hart AA, Baas P (1999) Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. *Lung Cancer* 25: 25-32. [Crossref]
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin for patients with malignant pleural mesothelioma. *J Clin Oncol* 21: 2636-2644. [Crossref]
8. Helland Å, Solberg S, Brustugun OT (2012) Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. *J Thorac Oncol* 7: 1858-1861. [Crossref]
9. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, et al. (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. *J Clin Oncol* 16: 145-152. [Crossref]
10. Henrond JE, Green MR, Chatterjee AP, Corson JM, Suzuki Y, et al. (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. *Chest* 113: 723-731. [Crossref]
11. Fennell DA, Parmar A, Shamas J, Evans MT, Sheaff MT, et al. (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. *J Clin Oncol* 23: 184-189. [Crossref]
12. Meniawy TM, Creamey J, Lake RA, Nowak AK (2013) Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma. *Br J Cancer* 109: 1813-1820. [Crossref]
13. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, et al. (2010) Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. *Ann N Y Acad Sci* 1203: 7-14. [Crossref]
14. Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: Feasibility, validity, and results of using the European organization for research and treatment of cancer core questionnaire and lung cancer module. *J Clin Oncol* 22: 3172-3180. [Crossref]
15. Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. *N Engl J Med* 353: 1591-1603. [Crossref]
16. Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. *Lancet* 366: 397-408. [Crossref]
17. Robinson BM (2012) Malignant pleural mesothelioma: an epidemiological perspective. *Ann Cardiothorac Surg* 1: 491-496. [Crossref]
18. Kao SC, Pavlikis N, Harvie R, Vardy J, Boyer MJ, et al. (2010) High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy. *Clin Cancer Res* 16: 5805-5813. [Crossref]
19. Kao SC, Vardy J, Chatfield M, Corte P, Pavlikis N, et al. (2013) Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. *Clin Lung Cancer* 14: 70-77. [Crossref]
20. Kao SC, Clarke S, Vardy J, Corte P, Clarke C, et al. (2013) Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. *Intern Med J* 43: 402-410. [Crossref]
21. Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, et al. (2012) Inflammation-based prognostic indices in malignant pleural mesothelioma. *J Thorac Oncol* 7: 587-594. [Crossref]
22. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, et al. (2011) Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant pleural mesothelioma undergoing extrapleuralpneumonectomy. *J Thorac Oncol* 6: 1923-1929. [Crossref]
23. Cedrés S, Montero MA, Martínez P, Martínez A, Rodríguez-Freixinos V, et al. (2012) Exploratory activation of expression of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). *Lung Cancer* 77: 192-198. [Crossref]
24. Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, et al. (2011) Chronic inflammation in tumour is an independent predictor of prolonged survival in epithelial malignant pleural mesothelioma patients. *Cancer Immunol Immunother* 60: 1721-1728. [Crossref]
25. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, et al. (2010) Pleural mesothelioma, in AJCC Cancer Staging Manual, Springer-Verlag: New York.
26. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. *J Surg Oncol* 91: 181-184. [Crossref]
27. Kishi Y, Kopez S, Chun YS, Palavecino M, Abdalla EK, et al. (2009) Blood Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Colorectal Liver Metastases Treated with Systemic Chemotherapy. *Ann Surg Oncol* 16: 614-622. [Crossref]
28. Gomez D, Morris-Stiff GF, Toosgoog GJ, Lodge JP, Prasad KR (2008) Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. *J Surg Oncol* 97: 513-518. [Crossref]
29. Chen JG, Chen WQ, Zhang SW, Zheng RS, Zhu J, et al. (2012) Incidence and mortality of liver cancer in China: an analysis on data from the National Registration System between 2003 and 2007. *Zhonghua Liu Xing Bing Xue Za Zhi* 33: 547-553. [Crossref]
30. Boffetta P (2007) Epidemiology of peritoneal mesothelioma: a review. *Ann Oncol* 18: 985-990. [Crossref]
31. Park EK, Takahashi K, Hoshuyama T, Cheng TJ, Delgermaa V, et al. (2011) Global magnitude of reported and unreported mesothelioma. *Environ Health Perspect* 119: 514-518. [Crossref]
32. Becklake MR, Bagatin E, Neder JA (2007) Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. *Int J Tuberc Lung Dis* 11: 356-369. [Crossref]
33. Lianes P, Remon J, Bover J, Ila D (2011) SEOM guidelines for the treatment of malignant pleural mesothelioma patients undergoing systemic therapy. *Clin Cancer Res* 16: 5805-5813. [Crossref]
34. Marinaccio A, Binizzi A, Cauzzillo G, Cavone D, Zotti RD, et al. (2007) Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. *Eur J Cancer* 43: 2722-2728. [Crossref]
35. Yeung P, Rogers A, Johnson A (1999) Distribution of mesothelioma cases in different occupational groups and industries in Australia, 1979-1995. *Aptil Occup Environ Hyg* 14: 759-767. [Crossref]
36. Burdorf A, Dahlan M, Swuste P (2003) Occupational characteristics of cases with asbestos-related diseases in The Netherlands. *Ann Occup Hyg* 47: 485-492. [Crossref]
